类泛素小分子NEDD8作为新型抗肺癌分子靶点鉴定及其机制研究
批准号:
81772459
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
王明松
依托单位:
学科分类:
H1815.肿瘤靶向治疗
结题年份:
2021
批准年份:
2017
项目状态:
已结题
项目参与者:
李立辉、谢晓、张韫佼、胡睿、何毅、王巍、卢荣鑫、孟礼飞、徐高俊
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
肺癌严重危害人类健康,亟待鉴定新型抗肺癌分子靶标,研发靶向药物。蛋白Neddylation修饰是通过酶促催化反应将类泛素分子NEDD8连接到底物上并调控底物构象与功能的过程。我们前期研究发现,Neddylation修饰关键催化酶和NEDD8本身在肺癌内高表达,与患者预后呈显著负相关,提示Neddylation通路活化促进肺癌发生发展。近期研究表明,NEDD8活化酶特异性小分子抑制剂有显著抗肺癌效果,但可诱导靶标突变产生耐药。鉴于NEDD8在肺癌内高表达,我们提出NEDD8作为针对Neddylation通路抗肺癌新靶标的假设。为检验该假设,本项目将研究NEDD8表达失调对肺癌细胞恶性表型的影响,系统评价靶向NEDD8抗肺癌的疗效,并阐明其效应机制。项目成功完成将揭示NEDD8高表达的促癌机理,鉴定NEDD8为新型抗肺癌分子靶点,为靶向Neddylation通路新药研发和靶向治疗提供科学依据。
英文摘要
Lung cancer badly endangers human health, which calls forto identifynovel anti-lung cancer target and develop new molecular inhibitors. Protein neddylation is athree-step enzymatic cascadewhich conjugates NEDD8 to targeted proteins and then regulates the conformation and function of thoestargeted proteins. Our preliminary study found that the key catalytic enzymes of Neddylation pathway and NEDD8 were highly expressed in lung cancer tissues and had a significant negative correlation with the prognosis of patients, suggesting that the over-activated Neddylation pathway promoted the development of lung cancer. Recent studies have revealed that even though small-molecule inhibitor of NEDD8-activating enzymeshowed significant antitumor effects on lung cancer,drug resistancewould be aroused by induced mutations of the targeted protein. Given the high expression level of NEDD8 in tumor tissue, we assumed NEDD8 as a new target of Neddylation pathway. To test this hypothesis, this project will examine the outcome of NEDD8 expression disorder on the malignant phenotypes of lung cancer cells and systematically evaluate the efficacy of targeting NEDD8 in the treatment of lung cancer, and then elucidate the underlying mechanism. This project will reveal the mechanism of high expression of NEDD8, identify NEDD8 as a new molecular target for lung cancer, and provide scientific basis for the development of novel drugs targeting Neddylation pathway.
肺癌严重危害人类健康,亟待鉴定新型抗肺癌分子靶标。蛋白Neddylation修饰是通过酶促催化反应将类泛素分子发育下调蛋白8(NEDD8)连接到底物上并调控底物构象与功能的过程,该通路的活化可促进肺癌发生发展。本项目通过利用CRISPR/cas9等技术研究NEDD8表达对肺癌细胞恶性表型的影响及其机制,发现了(1)NEDD8在肺腺癌中过表达与患者总体生存率低相关;(2)敲除NEDD8在体内外均可触发肺腺癌细胞衰老或凋亡;(3)敲除NEDD8使Cullin-RING泛素连接酶(CRL)系统失活;(4)NEDD8可作为NAE(E1)的替代靶点。充分且成功地验证了“NEDD8作为针对Neddylation通路抗肺癌新靶标”的假设。此外,一些细胞衰老相关蛋白,如MAPK14、MAPK1和MAP2K1等在NEDD8基因敲除肺腺癌细胞中发生了改变,这表明这些蛋白可能在NEDD8缺失诱导细胞衰老中发挥了致因作用,因此我们将对衰老相关蛋白网络是否参与及影响NEDD8作用机制展开进一步的研究。总之,本项目着重研究了NEDD8在促进肺腺癌发生进展中的作用,揭示了NEDD8的深层促癌机制,为NEDD8作为NAE(E1)替代靶点以治疗肺腺癌的靶向策略提供了科学依据及理论支持。在未来的研究中,我们将进一步阐述NEDD8作为治疗肺腺癌靶点的更多潜在机制。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway.
HAX1通过AKT/mTOR和MDM2/p53信号通路增强非小细胞肺癌的生存和转移
DOI:10.1111/1759-7714.13634
发表时间:2020-11
期刊:Thoracic cancer
影响因子:2.9
作者:Liang Z;Zhong Y;Meng L;Chen Y;Liu Y;Wu A;Li X;Wang M
通讯作者:Wang M
The CRL3BTBD9 E3 ubiquitin ligase complex targets TNFAIP1 for degradation to suppress cancer cell migration
CRL3(BTBD9) E3 泛素连接酶复合物靶向 TNFAIP1 进行降解,从而抑制癌细胞迁移
DOI:10.1038/s41392-020-0140-z
发表时间:2020-04-24
期刊:SIGNAL TRANSDUCTION AND TARGETED THERAPY
影响因子:39.3
作者:Li, Lihui;Zhang, Wenjuan;Jia, Lijun
通讯作者:Jia, Lijun
Reverse "L" surgical approach for the management of giant tumors of the cervicothoracic junction
逆“L”手术入路治疗颈胸交界处巨大肿瘤
DOI:10.21037/jtd-20-288b
发表时间:2020
期刊:Journal of Thoracic Disease
影响因子:2.5
作者:Zhong Yuan;Yang Xuhui;Jiang Lianyong;Hu Rui;Jiang Zhaolei;Wang Mingsong
通讯作者:Wang Mingsong
Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment
泛素样修饰剂 NEDD8 有效靶向治疗肺腺癌
DOI:10.1007/s10565-019-09503-6
发表时间:2020-08-01
期刊:CELL BIOLOGY AND TOXICOLOGY
影响因子:6.1
作者:Jiang, Yanyu;Cheng, Wei;Jia, Lijun
通讯作者:Jia, Lijun
类泛素小分子NEDD8调控GLUT5介导的果糖代谢促肺腺癌增殖转移的机制研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:55万元
- 批准年份:2020
- 负责人:王明松
- 依托单位:
国内基金
海外基金















{{item.name}}会员


